Noticias de CAPR_US
Noticias del mercado
Últimas noticias sobre CAPR_US — 926 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
/PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc....
¿Los fondos de cobertura están vendiendo en corto las acciones de Capricor Therapeutics (NASDAQ:CAPR)? Vea el índice de interés corto CAPR más reciente, el volumen corto y más en MarketBeat.
/PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between...
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Capricor Therapeutics Inc. stocks have been trading up by 13.75 percent following bullish sentiment on its clinical trial progress. Key Takeaways Wall Street upgrade and a steep price target hike have thrust CAPR onto more traders’ screens after Q2 2026. Shares ripped roughly 80–104% on FDA openness to an amended deramiocel filing and strong market…
Capricor Therapeutics Inc. stocks have been trading up by 13.75 percent after promising biotech progress boosted investor optimism. Key Takeaways For CAPR Traders Cantor Fitzgerald upgraded Capricor Therapeutics to Overweight and hiked its CAPR price target to $28 from $3.50 after Q2 earnings.
Capricor Therapeutics Inc. stocks have been trading up by 13.75 percent after promising biotech progress boosted investor optimism. Key Takeaways For CAPR Traders Cantor Fitzgerald upgraded Capricor Therapeutics to Overweight and hiked its CAPR price target to $28 from $3.50 after Q2 earnings.
Página 9 de 47